MindWalk Holdings (HYFT) Receivables (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Receivables of $1.8 million for Q2 2026, down 36.2% year-over-year from $2.9 million in Q2 2025, and up 35.97% quarter-over-quarter from $1.4 million in Q1 2026.
MindWalk Holdings (HYFT) Receivables (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Receivables for 7 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables fell 36.2% year-over-year to $1.8 million; the TTM figure through Apr 2026 stood at $1.8 million (down 36.2% YoY), while the FY2026 annual figure was $1.8 million, down 37.55% from the prior year.
- Receivables advanced to $1.8 million in Q2 2026 per HYFT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Receivables topped out at $3.0 million in Q4 2024 and bottomed at $1.3 million in Q3 2025.
- Historically, Receivables has averaged $2.2 million across 5 years, with a median of $2.3 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables soared 40.28% — and 2026, when it slumped 46.58%.
- MindWalk Holdings' Receivables stood at $2.4 million in 2022, then climbed by 9.79% to $2.7 million in 2023, then increased by 12.63% to $3.0 million in 2024, then retreated by 25.21% to $2.2 million in 2025, then retreated by 17.92% to $1.8 million in 2026.
- Business Quant data shows HYFT's Receivables at $1.8 million in Q2 2026, $1.4 million in Q1 2026, and $2.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.84 Mn |
| Jan 31, 2026 | 1.36 Mn |
| Oct 31, 2025 | 2.25 Mn |
| Jul 31, 2025 | 1.32 Mn |
| Apr 30, 2025 | 2.89 Mn |
| Jan 31, 2025 | 2.54 Mn |
| Oct 31, 2024 | 3.01 Mn |
| Jul 31, 2024 | 1.83 Mn |
| Apr 30, 2024 | 2.80 Mn |
| Jan 31, 2024 | 2.25 Mn |
| Oct 31, 2023 | 2.67 Mn |
| Jul 31, 2023 | 2.67 Mn |
| Apr 30, 2023 | 2.40 Mn |
| Jan 31, 2023 | 1.69 Mn |
| Oct 31, 2022 | 2.43 Mn |
| Jul 31, 2022 | 2.10 Mn |
| Apr 30, 2022 | 1.98 Mn |
| Jan 31, 2022 | 1.95 Mn |
| Oct 31, 2021 | 1.73 Mn |
| Jul 31, 2021 | 2.24 Mn |